Abbott Laboratories (NYSE:ABT) Given New $125.00 Price Target at Argus

Abbott Laboratories (NYSE:ABT) had its target price trimmed by Argus from $140.00 to $125.00 in a report published on Tuesday morning,MarketScreener reports. The firm currently has a buy rating on the healthcare product maker’s stock.

Other research analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Oppenheimer lowered their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $120.35.

Abbott Laboratories Trading Down 3.3%

NYSE ABT opened at $92.83 on Tuesday. The company’s 50-day moving average price is $107.21 and its 200-day moving average price is $118.00. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a market cap of $161.67 billion, a PE ratio of 26.00, a PEG ratio of 1.60 and a beta of 0.79. Abbott Laboratories has a 12 month low of $92.65 and a 12 month high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. State Street Corp raised its position in shares of Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors raised its position in shares of Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP raised its position in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors raised its position in shares of Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS kept a “buy” rating on ABT, signaling continued conviction in Abbott’s franchise despite trimming its price target — a vote of confidence from a major bank. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Income-minded investors are seeing value: recent coverage highlights a dividend yield near 3% and labels ABT a “dividend king” opportunity for buy-the-dip investors. That supports demand from yield-focused funds. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
• Positive Sentiment: Progress on Abbott’s CancerGuard multi-cancer early-detection program and new DETECT A outcomes reinforce the company’s long-term diagnostics growth narrative. Positive clinical/award news can support upside over time. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
• Neutral Sentiment: Options-market activity is drawing attention; spikes in put/call flows can foreshadow moves but aren’t a directional confirmation by themselves. Traders may use this as a signal for volatility, not fundamentals. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
• Neutral Sentiment: Coverage notes that ABT is trading near its 52-week low while many analysts remain bullish — an outlook that supports buy-side interest if sentiment stabilizes. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love
• Negative Sentiment: Major banks collectively trimmed price targets (multiple firm actions published), creating downward pressure on the stock as headline PT cuts refresh sell-side valuation estimates. This broad re-rating is a primary driver of today’s weakness. Mizuho Cuts Abbott Laboratories Price Target
• Negative Sentiment: UBS and Argus lowered their targets (UBS to $135; Argus to $125) even while keeping buy ratings — a mixed signal that reduces near-term upside expectations vs. prior levels. UBS Adjusts Abbott Laboratories Price Target to $135
• Negative Sentiment: Social and analyst chatter highlights that Q1 results beat estimates but management trimmed full-year guidance (diagnostics headwinds, mild flu season, acquisition costs), which triggered post-earnings selling and still weighs on sentiment. Abbott Laboratories Stock Opinions on Q1 Earnings and Guidance Cut

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.